NNVC

Business Context and Reporting Period

Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Nine months ended March 31, 2026
Business Overview: A clinical-stage nano-biopharmaceutical company developing broad-spectrum antiviral drugs using a host-mimicry nanomedicine platform. The Company operates from a cGMP-compliant facility in Shelton, Connecticut, and has no commercial product revenue to date.

Key Financial Metrics

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by approximately $1.38 million (18.7%) compared to the prior nine-month period, driven primarily by lower operating expenses.
• Expense Reduction: Total operating expenses declined by $1.42 million. R&D expenses decreased by $974,036 due to reduced outside lab fees for Phase II applications in the current period compared to the prior year. G&A expenses decreased by $411,929, attributed to lower professional fees for investor outreach.
• Capital Raising: The Company raised approximately $7.3 million in net proceeds during the period, significantly higher than the prior year. This included ~$1.9 million from At-The-Market (ATM) sales and ~$5.4 million from a Registered Direct Offering (RDO) and Private Placement in November 2025.
• Liquidity Improvement: Cash and cash equivalents increased by $1.65 million to $3.2 million, reversing the cash burn trend seen in the prior year period.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Milestones

• Lead Drug (NV-387): The Company is advancing NV-387, a broad-spectrum antiviral, into Phase II clinical trials. Key milestones include the submission of the Phase Ia/Ib clinical study report to Indian regulators and the initiation of a Phase II trial for MPox treatment in the Democratic Republic of Congo (DRC).
• Regulatory Designations: On April 27, 2026 (subsequent event), the FDA granted Orphan Drug Designation (ODD) for NV-387 for the treatment of Measles. Applications for MPox and Smallpox ODD are pending. The Company also filed for Rare Pediatric Disease Drug (RPDD) designation for Measles.
• Strategic Focus: Management is prioritizing "Orphan First" indications (Measles, MPox, Smallpox) to accelerate regulatory approval and access non-dilutive government funding (e.g., BARDA, NIH).

Risks and Contingencies

• Going Concern: The filing explicitly states substantial doubt exists regarding the Company's ability to continue as a going concern. Management believes current cash ($3.2 million) and a $3 million line of credit (undrawn) are insufficient to fund operations for the next 12 months.
• Financing Dependency: Continued operations depend on securing additional equity or debt financing and non-dilutive grants. There is no assurance such funding will be available on acceptable terms.
• Related Party Transactions: Significant liabilities and expenses are tied to related parties, including TheraCour Pharma (licensing/development fees) and Karveer Meditech (clinical trial costs). Accounts payable to related parties totaled $904,690 as of March 31, 2026.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.2 million cash balance against the projected burn rate for the upcoming Phase II MPox trial and general operations.
• Financing Pipeline: Confirm the status of the $3 million line of credit with Dr. Anil Diwan and any active discussions for new equity or grant funding.
• Clinical Trial Status: Monitor the timeline for the start of the Phase II MPox trial in DRC and the receipt of the final Phase I clinical study report.
• Regulatory Progress: Track the FDA's decision on the pending ODD applications for MPox and Smallpox, and the RPDD application for Measles.
• Related Party Exposure: Review the terms of the license agreements with TheraCour and the clinical trial agreements with KMPL to understand future royalty and milestone obligations.